Chirag Nepal1, Bin Zhu2, Colm J O'Rourke1, Deepak Kumar Bhatt1, Donghyuk Lee2, Lei Song2, Difei Wang2, Alison L Van Dyke2, Hyoyoung Choo-Wosoba2, Zhiwei Liu2, Allan Hildesheim2, Alisa M Goldstein2, Michael Dean2, Juan LaFuente-Barquero1, Scott Lawrence3, Karun Mutreja3, Mary E Olanich3, Justo Lorenzo Bermejo4, Catterina Ferreccio5, Juan Carlos Roa6, Asif Rashid7, Ann W Hsing8, Yu-Tang Gao9, Stephen J Chanock2, Juan Carlos Araya10, Jesper B Andersen11, Jill Koshiol12. 1. Biotech Research and Innovation Centre, Department of Health and Medical Sciences, University of Copenhagen, Denmark. 2. Division of Cancer Epidemiology and Genetics, NIH, Rockville, MD, USA. 3. Cancer Genomics Research Laboratory, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, MD, USA. 4. Statistical Genetics Research Group, Institute of Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany. 5. Department of Public Health, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile; Advanced Center for Chronic Diseases (ACCDiS), FONDAP, Santiago, Chile. 6. Department of Pathology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile. 7. Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 8. Stanford Cancer Institute and Stanford Prevention Research Center, Department of Medicine, Stanford School of Medicine, Stanford, CA, USA. 9. Department of Epidemiology, Shanghai Cancer Institute, Shanghai, China. 10. Advanced Center for Chronic Diseases (ACCDiS), FONDAP, Santiago, Chile; Hospital Dr. Hernán Henríquez Aravena, Temuco, Chile; Department of Pathology, Faculty of Medicine, Universidad de La Frontera, Temuco, Chile. 11. Biotech Research and Innovation Centre, Department of Health and Medical Sciences, University of Copenhagen, Denmark. Electronic address: jesper.andersen@bric.ku.dk. 12. Division of Cancer Epidemiology and Genetics, NIH, Rockville, MD, USA. Electronic address: koshiolj@mail.nih.gov.
Abstract
BACKGROUND & AIMS: Gallbladder cancer (GBC) is the most common type of biliary tract cancer, but the molecular mechanisms involved in gallbladder carcinogenesis remain poorly understood. In this study, we applied integrative genomics approaches to characterise GBC and explore molecular subtypes associated with patient survival. METHODS: We profiled the mutational landscape of GBC tumours (whole-exome sequencing on 92, targeted sequencing on 98, in total 190 patients). In a subset (n = 45), we interrogated the matched transcriptomes, DNA methylomes, and somatic copy number alterations. We explored molecular subtypes identified through clustering tumours by genes whose expression was associated with survival in 47 tumours and validated subtypes on 34 publicly available GBC cases. RESULTS: Exome analysis revealed TP53 was the most mutated gene. The overall mutation rate was low (median 0.82 Mut/Mb). APOBEC-mediated mutational signatures were more common in tumours with higher mutational burden. Aflatoxin-related signatures tended to be highly clonal (present in ≥50% of cancer cells). Transcriptome-wide survival association analysis revealed a 95-gene signature that stratified all GBC patients into 3 subtypes that suggested an association with overall survival post-resection. The 2 poor-survival subtypes were associated with adverse clinicopathologic features (advanced stage, pN1, pM1), immunosuppressive micro-environments (myeloid-derived suppressor cell accumulation, extensive desmoplasia, hypoxia) and T cell dysfunction, whereas the good-survival subtype showed the opposite features. CONCLUSION: These data suggest that the tumour micro-environment and immune profiles could play an important role in gallbladder carcinogenesis and should be evaluated in future clinical studies, along with mutational profiles. LAY SUMMARY: Gallbladder cancer is highly fatal, and its causes are poorly understood. We evaluated gallbladder tumours to see if there were differences between tumours in genetic information such as DNA and RNA. We found evidence of aflatoxin exposure in these tumours, and immune cells surrounding the tumours were associated with survival. Published by Elsevier B.V.
BACKGROUND & AIMS: Gallbladder cancer (GBC) is the most common type of biliary tract cancer, but the molecular mechanisms involved in gallbladder carcinogenesis remain poorly understood. In this study, we applied integrative genomics approaches to characterise GBC and explore molecular subtypes associated with patient survival. METHODS: We profiled the mutational landscape of GBC tumours (whole-exome sequencing on 92, targeted sequencing on 98, in total 190 patients). In a subset (n = 45), we interrogated the matched transcriptomes, DNA methylomes, and somatic copy number alterations. We explored molecular subtypes identified through clustering tumours by genes whose expression was associated with survival in 47 tumours and validated subtypes on 34 publicly available GBC cases. RESULTS: Exome analysis revealed TP53 was the most mutated gene. The overall mutation rate was low (median 0.82 Mut/Mb). APOBEC-mediated mutational signatures were more common in tumours with higher mutational burden. Aflatoxin-related signatures tended to be highly clonal (present in ≥50% of cancer cells). Transcriptome-wide survival association analysis revealed a 95-gene signature that stratified all GBC patients into 3 subtypes that suggested an association with overall survival post-resection. The 2 poor-survival subtypes were associated with adverse clinicopathologic features (advanced stage, pN1, pM1), immunosuppressive micro-environments (myeloid-derived suppressor cell accumulation, extensive desmoplasia, hypoxia) and T cell dysfunction, whereas the good-survival subtype showed the opposite features. CONCLUSION: These data suggest that the tumour micro-environment and immune profiles could play an important role in gallbladder carcinogenesis and should be evaluated in future clinical studies, along with mutational profiles. LAY SUMMARY: Gallbladder cancer is highly fatal, and its causes are poorly understood. We evaluated gallbladder tumours to see if there were differences between tumours in genetic information such as DNA and RNA. We found evidence of aflatoxin exposure in these tumours, and immune cells surrounding the tumours were associated with survival. Published by Elsevier B.V.
Authors: Jill Koshiol; Yu-Tang Gao; Michael Dean; Patricia Egner; Chirag Nepal; Kristine Jones; Bingsheng Wang; Asif Rashid; Wen Luo; Alison L Van Dyke; Catterina Ferreccio; Michael Malasky; Ming-Chang Shen; Bin Zhu; Jesper B Andersen; Allan Hildesheim; Ann W Hsing; John Groopman Journal: Gastroenterology Date: 2017-04-17 Impact factor: 22.682
Authors: Peng Jiang; Shengqing Gu; Deng Pan; Jingxin Fu; Avinash Sahu; Xihao Hu; Ziyi Li; Nicole Traugh; Xia Bu; Bo Li; Jun Liu; Gordon J Freeman; Myles A Brown; Kai W Wucherpfennig; X Shirley Liu Journal: Nat Med Date: 2018-08-20 Impact factor: 53.440
Authors: Ludmil B Alexandrov; Philip H Jones; David C Wedge; Julian E Sale; Peter J Campbell; Serena Nik-Zainal; Michael R Stratton Journal: Nat Genet Date: 2015-11-09 Impact factor: 38.330
Authors: Li Wang; Xiaomo Li; Yurong Cheng; Jing Yang; Si Liu; Tonghui Ma; Li Luo; Yanping Hu; Yi Cai; Dong Yan Journal: Front Immunol Date: 2022-01-06 Impact factor: 7.561